2024 Compassher2-pcr

Compassher2-pcr

Author: hdcf

August undefined, 2024

WebThe COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD) A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib NYU Langone Health Perlmutter Cancer Center WebJul 15, 2024 · The [phase 2] CompassHER2-pCR [NCT04266249] and Decrescendo [NCT04675827] trials are looking at neoadjuvant [paclitaxel, trastuzumab, and pertuzumab], the THP regimen, and then de-escalating in ...

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR …

WebEA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of:The CompassHER2 Trials (COMprehensive use of Pathologic response Assessment to optimize therapy in HER2-positive breast cancer). PSCI-20-133 WebJan 10, 2024 · This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no … primary health ellwood city

CompassHER2-pCR: Decreasing Chemotherapy for Breast …

WebThe CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib 202403185 A Phase II Study of U3-1402 in Patients With Metastatic Breast … WebMay 10, 2024 · The CompassHER2-pCR trial (NCT04266249) is ongoing and will determine recurrence-free survival among patients with HER2+ breast cancer who … WebEA1181/CompassHER2 pCR Eligibility Criteria* Main Inclusion Criteria • ≥ 18 years of age with histologically confirmed HER2+ primary invasive breast carcinoma, as determined by local testing. Tumor must have either HER2 IHC result of 3+ or HER2/CEP17 ratio ≥ 2 with ≥ 4.0 HER2 signals per cell by ISH. Tumors with primary health dental clinic

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 - Journal of …

CTSU/EA1181 SWOG

WebSep 17, 2024 · Looking to the future, de Azambuja concludes that, “Two interesting trials are currently exploring other de-escalation approaches. The CompassHER2-pCR trial is evaluating the impact of de-escalating chemotherapy in patients achieving pCR and escalating treatment in those with residual disease. WebMay 18, 2024 · One example is a trial that’s really looking at de-escalation of therapy in this setting. For example, CompassHER2-pCR is a large cooperative group trial, which is looking at preoperative THP [docetaxel, trastuzumab, pertuzumab]—for 12 weeks, trastuzumab, and pertuzumab. primary health drug screenWebMar 29, 2024 · COMPASSHER2-pCR To test whether it is safe to eliminate additional chemotherapy after surgery • HER2-positive breast cancer diagnosis ... COMPASSHER2 To test if the combination of T-DM1 and a newer drug tucatinib is better than usual treatment with T-DM1 alone at preventing cancer from player access resorts atlantic city

"WebAlliance-A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib. " - Compassher2-pcr

Compassher2-pcr

WebPatient must have histologically confirmed HER2-positive primary invasive breast carcinoma, determined by local testing. The tumor must have either HER2 IHC result of … WebEA1181 / CompassHER2 pCR Preoperative THP & Postoperative HP in Patients who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 …

Did you know?

WebApr 15, 2024 · The CompassHER2 (COMprehensive use of Pathologic response ASSessment to escalate or de-escalate therapy in HER2-positive breast cancer) Trial … WebDECRESCENDO Trial (which is very similar to CompassHER2 pCR in terms of study design, drugs, and eligibility). However, patients who received 4 cycles of neoadjuvant THP off study can receive a further 2-4 cycles of chemotherapy postoperatively to meet eligibility for A011801. Patients who participated in EA1181 or MA41 and proceeded to

WebPatient must have histologically confirmed HER2-positive primary invasive breast carcinoma, determined by local testing. The tumor must have either HER2 … WebThe CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease …

WebCompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (Study ID ... therapy, consisting of HER2-directed therapy, radiation (if indicated) and endocrine therapy (if ER+) if achieving pCR at surgery; Patient with bilateral invasive breast cancers are eligible if both cancers are HER2 ... Web(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Eligibility Criteria Ages Eligible for Study: Older than 18 …

WebARM A: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Patients may substitute trastuzumab-hyaluronidase SC over 2-5 minutes on day 1 in place of trastuzumab or pertuzumab-trastuzumab-hyaluronidase SC over 5 minutes on day 1 in place of trastuzumab and pertuzumab. Treatment repeats every 21 days for up to 13 ...

WebSep 20, 2024 · Ongoing neoadjuvant trials like ECOG-ACRIN EA1181 CompassHER2 pCR in HER2-positive disease (ClinicalTrials.gov identifier: NCT04266249) and Alliance ALTERNATE in HR-positive disease (ClinicalTrials.gov identifier: NCT01953588) are addressing chemotherapy de-escalation questions using survival as the primary objective. player accountsWebFeb 11, 2024 · Tumors with HER2/CEP17 ISH ratio < 2 are ineligible, even if HER2 copy number is > 6, unless HER2 IHC result is 3+. - Patients hormone receptor (estrogen … playera celineWebClinical Trial Title. The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 … playera chalinoWebFeb 11, 2024 · SWOG clinical trial number. CTSU/EA1181. (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response. Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer) … playera champion blancaWebNov 1, 2024 · CompassHER2-pCR aims to avoid excess toxicity from unnecessary chemotherapy in patients who have a pCR to THP, and CompassHER2 RD aims to … playera champion playera chalino sanchezWebMay 18, 2024 · I’m going to let everybody know about a very important trial called CompassHER2-pCR, which offers the potential to avoid both anthracycline and carboplatin. I want to nickname this the “let’s get rid of carboplatin” trial. primary health eagle rd